Lornoxicam for injection

This product is a non-steroidal anti-inflammatory analgesic, a thiazide derivative, with strong analgesic and anti-inflammatory effects. Its mechanism of action includes: 1. Inhibiting the synthesis of prostaglandins by inhibiting the activity of cyclooxygenase (COX); but it does not inhibit the activity of 5-lipid oxidase, so it does not inhibit the synthesis of leukotrienes, nor does it shunt arachidonic acid to the 5-lipid oxidase pathway. 2. Activate the opioid neuropeptide system to exert a central analgesic effect. Animal safety studies have shown that the toxicity characteristics are consistent with the inhibition of half of the oxidase. The digestive tract and kidneys are the most sensitive organs to toxic effects. Animal test results show that lornoxicam for injection has no vascular irritation and muscle irritation, and does not cause allergies and hemolysis.

Lornoxicam. Its chemical name is 6-chloro-4-hydroxy-2-methyl-3-(2-pyridinecarbamoyl)-2H-thieno[2,3e]1,2-thiazine-1,1-dioxide. Molecular formula: C13H10CIN3O4S2 Molecular weight: 371.82

Acute moderate postoperative pain and pain associated with acute lumbar and sciatica.

Intramuscular (5 seconds) or intravenous (15 seconds) injection. Dissolve the product in 2 ml of water for injection before injection. Dilute with at least 2 ml of 0.9% NaCl injection solution for intravenous injection. The conventional dose of this product is: starting dose 8 mg. If 8 mg does not adequately relieve pain, 8 mg can be added once. In some cases, an additional 8 mg may be required on the first day after surgery, i.e. the maximum dose for the day is 24 mg. The dose of this product is 8 mg thereafter, twice a day. The daily dose should not exceed 16 mg.

Adverse reactions with an incidence of more than 10%: no adverse reactions related to the injection site (such as pain, redness, tingling, tension), stomach pain, nausea, vomiting, dizziness, drowsiness, increased drowsiness, headache, skin flushing. Adverse reactions with an incidence of less than 1%: flatulence, restlessness, indigestion, diarrhea, increased blood pressure, palpitations, chills, sweating, taste disorders, dry mouth, leukopenia, thrombocytopenia, urination disorders.

1. Patients who are allergic to lornoxicam are prohibited from using this product; 2. Patients who are allergic to nonsteroidal anti-inflammatory drugs (such as acetylsalicylic acid) are prohibited from using this product; 3. Patients with bleeding constitution, coagulation disorder, or patients who are at risk of bleeding during surgery or have an imperfect coagulation mechanism are prohibited from using this product; 4. Patients with acute gastric/intestinal bleeding or acute gastric or intestinal ulcers are prohibited from using this product; 5. Patients with moderate to severe renal impairment are prohibited from using this product; 6. Patients with cerebral hemorrhage or suspected cerebral hemorrhage are prohibited from using this product; 7. Patients with massive blood loss or dehydration are prohibited from using this product; 8. Patients with severe liver damage are prohibited from using this product; 9. Patients with severe heart damage are prohibited from using this product;

Precautions during pregnancy and lactation: Contraindicated for use by pregnant or lactating patients.

If this product is used at the same time as other medicines, its effect may be different. This is especially important in the following situations: 1. Use with anticoagulants or blood thinners; 2. Use with ACE (angiotensin converting enzyme) inhibitors; 3. Use with nonsteroidal anti-inflammatory drugs with the same effect as this product; 4. Use with diuretics; 5. Use with oral antidiabetic drugs; 6. Use with lithium preparations; 7. Use with medicines containing methotrexate; 8. Use with medicines containing cimetidine; 9. Use with medicines containing digoxin.

Protect from light and store in a cool and dry place.

8mg (each bottle actually contains 8.6mg of lornoxicam)

Suzhou Tianma PHARMA Group Tianji BIO-PHARMACEUTICAL Co., Ltd.

• Founded in:

  2000-06-21

• Address:

  No. 199, Huayuan East Road, Mudu Town, Wuzhong District, Suzhou City

• Tax NO.:

  91320506720538941C

• Registered Funds:

  220 million yuan

• Website:

  Log in to view

• Email:

  Log in to view